NORVAX UK is leading the development of the mRNA Universal Coronavirus Vaccine (mRNA-UCV) and is leading the mRNA UCV Consortium, Vaxcomm and Norsk Vaksinefabrikk.

The goal of the mRNA Universal Coronavirus Vaccine is to help solve the urgent global need for a one-time COVID-19 booster to save lives and help to end the COVID-19 pandemic and to support innovation for future pandemic preparedness.

Located in Sandefjord, 12 minutes from TORP International, Norsk Vaksinefabrikk plans to be a leading CDMO export business in Norway with planned cGMP capacity for delivery of 1.2 billion mRNA-UCV doses in 2022/23. 

With Norsk Vaksinefabrikk development of the mRNA Vaccine Platform in cooperation with SINTEF and strategic technology vendors, scientists at mRNA UCV Consortium, NORVAX UK and Norsk Vaksinefabrikk will program multiple mRNA targets on the virus for delivery of a Universal Coronavirus Vaccine for SARS-CoV-2 Variants of Concern (VOC) including Alpha, Beta, Gamma, Delta VOCs, and expected future SARS-CoV-2 VOCs.

The mRNA Vaccine Platform for the mRNA UCV flagship product development, NORVAX UK, Norsk Vaksinefabrikk, mRNA UCV Consortium, and members of Vaxcomm – The Vaccine Commons, are openly supported to apply the mRNA Vaccine Platform to develop novel mRNA vaccines for infectious disease, therapeutics and cancers.

Norsk Vakisinefabrikk by Norvax AS

Norsk Vaksinefabrikk at Borgeskogen 65, Sandefjord. 

Norsk Vaksinefabrikk is located in the industrial park at Borgeskogen, Sandefjord, 12 minutes from TORP international airport for global access to highly profitable and sustainable biopharmaceutical export service products for COVID-19, infectious disease and global epidemic preparedness – truly a ‘forever market need’.

The First Vaccine Factory in Norway for Pandemic Preparedness

With a focus on partnership and open science we are developing the future of biological medicines through shared scientific expertise, agility and innovation, for the COVID-19 pandemic and long-term sustained pandemic preparedness. Our vision is to create an ecosystem for biological medicines, ‘Norsk Vaksinefabrikk’, where research and development will co-exist with established GMP manufacturing.

Production of safe and effective mRNA Vaccines at industrial scale is planned to commence in 2022/23 for export to the UK, EU and international markets.

Learn More About Us

Visit Website
Visit Website
Visit Website
Visit Website
Visit Website


MERS Coronavirus Case Fatality Rate is 35%. One in three infections result in DEATH.
Likelihood of increased [SARS-CoV-2] severity phenotype: Realistic possibility. (SAGE)